Clinical Trial Update: VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia [Phase 2]

View source ↗

Summary

Phase 2 study of VNP40101M in acute myeloid leukemia and high-risk myelodysplastic syndromes has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• VNP40101M

Snippet

Sponsor: Vion Pharmaceuticals | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED